Fachbereich Veterinärmedizin



    Untersuchungen zur Wirksamkeit, Verträglichkeit und Sicherheit des ACE-Hemmers Ramipril bei Katzen mit Kardiomyopathien sowie bei Katzen mit Kardiomyopathien ud Hypertension (2001)

    Schille, Jörg-Florian
    Berlin, 2001 — 120 Seiten
    Klinik für kleine Haustiere

    Oertzenweg 19 b
    Haus 1
    14163 Berlin
    +49 30 838 62356

    Abstract / Zusammenfassung

    Angiotensin converting enzyme inhibitors have long been recognized as an effective treatment for heart insufficiencies in human medicine and in canine veterinary medicine and for human hypertension. However, only a few studies on the use of ACE inhibitors for cats have been carried out to date. In the following study this drug group is administered to hypertensive and normotensive cats suffering from hypertrophic cardiomyopathy. The aim of this study is to evaluate the effectiveness , the tolerance levels and the safety of the ACE inhibitor Ramipril for cats.Fifty-four cats suffering from heart disorders are monitored and the course of their illness is documented for periods ranging from 2 months to 2 years. Initially a general examination is carried out followed by specific cardiological examinations including blood pressure monitoring, radiological examinations, electrocardiograms and echocardiograms and blood screening. This study presents, in the first place, an overview of the clinical symptoms of cats with heart disorders diagnosed during cardiological examinations. Secondly clinical findings derived from the first examinations are compared with the results of control examinations and thus the effectiveness of Ramipril is documented- Various blood values and the blood pressure are monitored in order to detect possible side effects of Ramipril.Twenty-six of the 54 cats treated have been diagnosed with hypertension and a hypertrophied myocard (Group A). Twenty-two cats are normotensive and suffer from hypertophic cardiomyopathy (Group B). Four of the remaining 6 cats show signs of hyperthyroidism and 2 cats suffer from dilatative cardiomyopathy (Group C).The cats are treated either with Ramipril only (n=13) or, the majority (n=41), with a combined therapy using loop diuretics.The dose recommended for dogs (1 x day 0,125 mg/kg Ramipril) proves to be adequate in most cases and improves the clinical symptoms of cats. While normotensive cats do not show a significant blood pressure decrease, however a decrease can be measured in hypertensive patients. A regression of existing cardiomyopathies can not be statistically evaluated; one of the echocardiographic parameters obtained improves in 54, 1 % of cats.The renal blood values measured throughout the study rise in certain cats, in others they sink. Thanks to the small number of side effects, in none of the cases the administration of Ramipril had to be discontinued.When the administration of Ramipril is combined with thyreostatics in cats suffering from hyperthyroidism, both drugs prove to be effective and do not show side effects. The same applies to combined therapies with Ramipril and B-Methyldigoxin in cats with dilative cardiomyopathy.